-
Olema Pharmaceuticals NASDAQ:OLMA Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist, and a selective ER degrader (SERD). OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase4 (CDK4)/6 demonstrated robust tumour shrinkage in several xenograft models, including a breast cancer brain metastasis model.
Location: | Website: www.olemapharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
100.7M
Cash
214.8M
Avg Qtr Burn
N/A
Short % of Float
35.54%
Insider Ownership
3.21%
Institutional Own.
85.86%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OP-1250 (palazestrant) (CER antagonist) Details Metastatic breast cancer, Cancer | Phase 3 Data readout | |
Palazestrant (OP-1250) + ribociclib Details ER+/HER2- breast cancer, Cancer | Phase 3 Initiation | |
OP-1250 (palazestrant) +palbociclib Details Metastatic breast cancer, Breast cancer, Cancer | Phase 1/2 Update | |
OP-1250 (palazestrant) + ribociclib or alpelisib Details Breast cancer, Metastatic breast cancer, Cancer | Phase 1/2 Update | |
OP-1250 (palazestrant) + everolimus Details Metastatic breast cancer, Breast cancer, Cancer | Phase 1/2 Initiation | |
OP-3136 Details Cancer, ER+/HER2- breast cancer | Phase 1 Initiation |